Today: 19 March 2026
Subscribe
Browse Category

Biotechnology 15 October 2025 - 18 October 2025

Sellas Life Sciences (SLS) Stock Rallies on Promising Leukemia Data – Analysts Eye Triple-Digit Upside

Sellas Life Sciences (SLS) Stock Rallies on Promising Leukemia Data – Analysts Eye Triple-Digit Upside

Sellas Life Sciences (NASDAQ:SLS) closed near $2.14 on Oct. 17, up about 100% year-to-date, with trading volatility and a 761% surge in call options on Oct. 14. Its GPS immunotherapy remains in Phase 3, while SLS009 showed strong preclinical results and a 44% response rate in Phase 2 AML data. Sellas raised $23.6M in September and had $25.3M cash at June 30. Analyst targets range from $6–7, with short interest at 18%.
18 October 2025
··
MindMed Stock Skyrockets on Psychedelic Breakthroughs – What’s Driving the MNMD Surge?

MindMed Stock Soars 15% to 52-Week High on Psychedelic Breakthrough – What’s Next for MNMD?

MindMed (NASDAQ: MNMD) closed at $13.65 on Oct. 17, up 14.6% in one day and 68% year-to-date, after its LSD-based therapy MM120 showed strong Phase 2b results for Generalized Anxiety Disorder. The FDA granted Breakthrough Therapy status to MM120, with three Phase 3 trials underway. Needham & Co. initiated coverage with a Buy rating and $28 target. MindMed holds $237.9 million in cash, funding operations into 2027.
18 October 2025
··
Gilead Sciences (GILD) Stock Soars on Patent Victory, HIV Breakthroughs, and Analyst Upgrades

Gilead Sciences Stock Soars on Patent Win and HIV Breakthroughs – Will the Rally Continue?

Gilead Sciences stock jumped over 4% on Oct. 17, 2025, closing at $122.81 and hitting a new 52-week high. The surge follows a patent settlement extending exclusivity for Biktarvy until 2036 and FDA approval of Yeztugo, a new HIV prevention shot. Gilead’s market cap stands near $150 billion after a 47% year-to-date gain. Analysts remain bullish but note concerns over U.S. drug pricing pressures.
18 October 2025
···
MindMed Stock Skyrockets on Psychedelic Breakthroughs – What’s Driving the MNMD Surge?

MindMed Stock Skyrockets on Psychedelic Breakthroughs – What’s Driving the MNMD Surge?

MindMed shares hit a 52-week high of $13.09 this week after its LSD-based drug MM120 showed strong Phase 2b results for generalized anxiety disorder and received FDA Breakthrough Therapy designation. The stock is up about 68% year-to-date. Analysts set average price targets near $27.83. MindMed holds $237.9 million in cash, funding operations into 2027.
18 October 2025
··
Gilead Sciences (GILD) Stock Soars on Patent Victory, HIV Breakthroughs, and Analyst Upgrades

Gilead Sciences (GILD) Stock Soars on Patent Victory, HIV Breakthroughs, and Analyst Upgrades

Gilead Sciences shares rose to $123 on October 17, 2025, up nearly 40% from a year ago, lifting its market value to about $150 billion. The company settled U.S. patent litigation over HIV drug Biktarvy, blocking generics until 2036. Its new HIV prevention shot Yeztugo is seeing strong uptake, and Moody’s raised Gilead’s outlook to “Positive.” Gilead also announced a $1.5 billion cell therapy deal with Pregene.
17 October 2025
··
Kezar Life Sciences Stock Soars 40% After FDA Setback Sparks Strategic Shake-Up

Kezar Life Sciences Stock Soars 40% After FDA Setback Sparks Strategic Shake-Up

Kezar Life Sciences said the FDA canceled a key meeting and imposed new trial demands for its lead drug zetomipzomib, delaying development by about two years. The company is now exploring a sale or merger and cutting costs. Shares jumped nearly 40% to $6 on Oct. 17. Kezar reported $90.2 million in cash as of Sept. 30 but faces higher expenses and extended a poison pill plan to 2026.
17 October 2025
··
Achieve Life Sciences Skyrockets on FDA Boost – Is This Nicotine Addiction Breakthrough a Game Changer?

Achieve Life Sciences Skyrockets on FDA Boost – Is This Nicotine Addiction Breakthrough a Game Changer?

Achieve Life Sciences shares jumped over 20% in pre-market trading Friday after receiving an FDA Commissioner’s National Priority Voucher for its lead drug, cytisinicline. The FDA also accepted Achieve’s New Drug Application for cytisinicline as a smoking cessation treatment, with a decision expected by June 2026. ACHV stock reached multi-month highs near $3 following the news. The company’s market cap is about $160 million.
17 October 2025
··
Biotech Breakthrough: GRAIL (GRAL) Stock Surges on New Cancer-Detection Data

GRAIL (GRAL) Rockets to Record High on Samsung Mega-Deal and Cancer Test Breakthrough

GRAL stock surged 14% to a record $86 after Samsung agreed to invest $110 million and help launch GRAIL’s Galleri cancer blood test in Asia. New trial data showed the test doubled early cancer detection rates. GRAIL shares are up over 300% this year, valuing the company at $2.7 billion. Most analysts rate the stock “Hold,” with average targets well below current prices.
17 October 2025
····
Femasys (FEMY) Rockets on Fertility Breakthroughs and FDA Milestones – What’s Behind the Surge?

Femasys (FEMY) Rockets on Fertility Breakthroughs and FDA Milestones – What’s Behind the Surge?

Femasys Inc. shares surged 46% intraday on Oct. 16, 2025, closing up 35% at $0.745 amid heavy trading. The rally followed news of regulatory approvals for its FemBloc® birth control system in Europe, UK, and New Zealand, and a major order from a Spanish distributor. The company also announced new partnerships and showcased its fertility treatments at an industry conference. Femasys remains unprofitable but reported 85% year-over-year sales growth in Q2.
17 October 2025
··
Praxis (PRAX) Stock Skyrockets 180% on Game-Changing Tremor Drug Trial; Analysts See ‘Blockbuster’ Upside

Praxis (PRAX) Stock Skyrockets 180% on Game-Changing Tremor Drug Trial; Analysts See ‘Blockbuster’ Upside

Praxis Precision Medicines shares jumped 180% to $162 on Oct. 16 after its lead drug, ulixacaltamide, met all key endpoints in two Phase 3 trials for essential tremor. The rally added nearly $3 billion to the company’s market cap. Praxis announced a $525 million public offering to fund commercialization and pipeline expansion. Analyst price targets surged, with several now above $250.
17 October 2025
··
GRAIL Inc. Stock Rises on Samsung Partnership and Cancer-Test News

GRAIL Inc. Stock Rises on Samsung Partnership and Cancer-Test News

GRAIL shares jumped 13.6% to close at $85.82 on Oct. 16 after announcing a $110 million equity investment and distribution deal with Samsung C&T and Samsung Electronics. Samsung C&T will exclusively distribute GRAIL’s Galleri cancer test in South Korea, with possible expansion to Japan and Singapore. GRAL’s market cap rose to about $2.7 billion. Most analysts maintain a Hold rating despite the stock’s 321% year-to-date gain.
16 October 2025
···
Moderna’s Wild Ride: Vaccine Hopes Fuel Stock Pop Amid “One-Hit Wonder” Fears

Moderna’s Wild Ride: Vaccine Hopes Fuel Stock Pop Amid “One-Hit Wonder” Fears

Moderna shares rose 5% to $28 but remain down 35% in 2024 and nearly 80% below last year’s level. COVID vaccine sales have collapsed from $18.9 billion in 2022 to $3.1 billion, and Q2 revenue fell 41% to $142 million. The company cut its 2025 revenue forecast and is laying off 10% of staff. Early data from an experimental cancer vaccine showed a 24% tumor response rate in advanced melanoma.
16 October 2025
··
Praxis Precision (PRAX) Stock Skyrockets on Game-Changing Phase 3 Results – What Experts Say

Praxis Precision (PRAX) Stock Skyrockets on Game-Changing Phase 3 Results – What Experts Say

Praxis shares soared nearly 180% premarket Oct. 16 after positive Phase 3 results for ulixacaltamide in essential tremor, hitting a new 52-week high. The drug met all primary and secondary endpoints in two trials and showed no serious safety issues. Praxis plans to seek FDA approval by early 2026. The company reported a Q2 net loss of $71.1M but held $446M in cash at mid-2025.
16 October 2025
··
Sana Biotechnology (SANA) Stock Skyrockets on ‘100-Bagger’ Hype – Experts Debate What’s Next

Sana Biotechnology (SANA) Stock Skyrockets on ‘100-Bagger’ Hype – Experts Debate What’s Next

Sana Biotechnology shares jumped 26% to $5.62 on Oct. 15 after hedge fund manager Eric Jackson called the stock a potential “100-bagger” on X, triggering volatility halts. The rally followed early trial results showing transplanted pancreatic cells produced insulin without immunosuppressive drugs. Sana raised $105 million in summer 2025, extending its cash runway into late 2026. Analyst ratings remain mixed, with targets ranging from $5 to $12.
16 October 2025
··
Omeros Stock Explodes 146% on Surprise $2.1B Novo Nordisk Deal – What Comes Next?

Biotech Bombshell: Omeros Stock Skyrockets on $2.1B Novo Nordisk Deal – What’s Next?

Omeros shares soared 150% to $10.42 on Oct. 15 after Novo Nordisk agreed to license its drug zaltenibart (OMS906) for $340 million upfront and up to $2.1 billion in milestones and royalties. Trading volume hit 89.2 million shares, far above average. Omeros reported a Q2 net loss of $25.4 million and $28.7 million in cash as of June 30. Its lead asset narsoplimab remains under FDA and EMA review.
16 October 2025
···
Sana Biotech Shares Skyrocket on 100x Hype – What’s Behind the Rally?

Sana Biotech Shares Skyrocket on 100x Hype – What’s Behind the Rally?

Sana Biotechnology shares jumped 26% to $5.62 on Oct. 15 after hedge fund manager Eric Jackson called the stock “the next 100-bagger” on social media. Trading was briefly halted during the surge. The company recently reported positive diabetes cell-therapy trial data and raised $105 million, extending its cash runway into late 2026. Analyst price targets range from $5 to $12, with a consensus near $7.50.
15 October 2025
··
Recursion RXRX Stock Skyrockets: AI Breakthroughs and Big Pharma Deals Ignite Biotech Surge

Recursion RXRX Stock Skyrockets: AI Breakthroughs and Big Pharma Deals Ignite Biotech Surge

Recursion Pharmaceuticals’ stock jumped about 16% to $6.08 on Oct. 8, 2025, after renewed interest in its AI-driven drug discovery platform. The company reported Q2 revenue of $19.2 million and a net loss of $171.9 million, ending the quarter with $534 million in cash. Management cut 20% of staff in mid-2025 to reduce costs. Analyst targets average $6.50, with mixed ratings.
15 October 2025
···
Origin Agritech’s SEED Stock Skyrockets 92% on China Seed Breakthroughs & Trade Buzz

Origin Agritech’s SEED Stock Skyrockets 92% on China Seed Breakthroughs & Trade Buzz

Origin Agritech (NASDAQ: SEED) surged 92% in after-hours trading on Oct. 14, then fell back near $1.43 by Oct. 15. The Beijing agri-tech firm re-entered Northeast China, showcased new hybrid corn seeds, and announced a partnership with Fengtian Seed Industry. CEO Weibin Yan invested $2.4 million in September, with institutions adding $1.48 million. The stock spike followed U.S.-China trade tensions that lifted agriculture shares.
15 October 2025
·
Evaxion (NASDAQ:EVAX) Stock Rockets After AI-Powered Cancer Vaccine Breakthrough

Evaxion (NASDAQ:EVAX) Stock Rockets After AI-Powered Cancer Vaccine Breakthrough

Evaxion shares jumped 25% on Oct 14, closing at $7.84, after Merck exercised its option on the EVX-B3 vaccine, paying $7.5 million upfront with up to $592 million in milestones. Evaxion will present two-year Phase 2 data for its AI-designed melanoma vaccine at ESMO on Oct 17. The company also announced an upgrade to its AI-Immunology platform and maintains a “Strong Buy” rating from analysts.
15 October 2025
···
Arcadia Biosciences Stock Rockets Amid Trade News – What’s Behind RKDA’s Wild Ride?

Arcadia Biosciences Stock Rockets Amid Trade News – What’s Behind RKDA’s Wild Ride?

Arcadia Biosciences (RKDA) stock soared 68% pre-market Oct 15 to $6.22 after President Trump tweeted about ending some cooking-oil trade with China, sparking a sector rally. The company’s Q2 revenue rose 11% to $1.455 million, all from Zola coconut water, but it posted a $4.46 million net loss due to a $4.5 million write-off on a note from Above Food. The planned merger with Roosevelt Resources remains pending.
15 October 2025
···
1 … 12 13 14 15 16

Stock Market Today

  • Bluesky raises $100M Series B amid CEO transition and rapid user growth
    March 19, 2026, 4:59 PM EDT. Bluesky, a social network built on the decentralized AT Protocol, announced a $100 million Series B funding round led by Bain Capital Crypto. The round, closed in April 2025 but disclosed recently, follows previous Series A and seed rounds. The funding comes as CEO Jay Graber steps down to become chief innovation officer, aiming to bring in leadership focused on commercial growth. Bluesky's user base has surged from 13 million to over 43 million globally, with its interoperable app ecosystem expanding. Despite crypto-focused investors, Bluesky has not integrated cryptocurrencies or blockchain technology directly, though its decentralized design attracts crypto interest. The new capital will help scale the team and enhance Bluesky's app and developer ecosystem, now comprising about 20 billion public data records and over 1,000 apps built on AT Protocol.
Go toTop